Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05921253 · ClinicalTrials.gov registry record · Early Phase 1

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

A Early Phase 1 study of Breast Cancer and Lymphoma, sponsored by University of Oklahoma.

Recruiting
Registry status
Early Phase 1
Development phase
104
Enrollment target
2
Study locations

NCT05921253 is a Early Phase 1 study of Breast Cancer and Lymphoma that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 104 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05921253, a Early Phase 1 study of Breast Cancer and Lymphoma, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
Early Phase 1
Development phase
104 participants
Enrollment target
2
Study locations

Study Summary

This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

Conditions Studied

Breast Cancer Lymphoma

Interventions

  • DEVICE PARASYM neuromodulation device

Study Locations (2)

Oklahoma

  • Stephenson Cancer Center - Oklahoma City
  • Stephenson Cancer Center- Tulsa - Tulsa

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2023-12-01
Est. Completion 2027-09
Phase Early Phase 1

Sponsor

University of Oklahoma

358 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05921253

The ClinicalTrials.gov registry entry for NCT05921253 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PARASYM neuromodulation device is the first listed.

NCT05921253 reports 2 study locations spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT05921253 about?

NCT05921253 is a clinical study titled "Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy". This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

What is the current status of trial NCT05921253?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 104 participants. The study started on 2023-12-01. Estimated completion is 2027-09.

What conditions does trial NCT05921253 study?

This clinical trial studies the following conditions: Breast Cancer, Lymphoma.

What interventions are being tested in trial NCT05921253?

The interventions under investigation include: PARASYM neuromodulation device (DEVICE).

Who is sponsoring clinical trial NCT05921253?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05921253 being conducted?

This trial has 2 study locations across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Lymphoma

All registered trials for this condition

Oklahoma

All trials with a study site in Oklahoma

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.